STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF LONG-ACTING INTRAMUSCULAR CABOTEGRAVIR AND RILPIVIRINE FOR MAINTENANCE OF VIROLOGIC SUPPRESSION FOLLOWING SWITCH FROM AN INTEGRASE INHIBITOR IN HIV-1 INFECTED THERAPY NAIVE PARTICIPANTS: